Zai Lab Ltd ADR (NQ: ZLAB )
33.27 -0.46 (-1.36%) Streaming Delayed Price Updated: 11:36 AM EDT, Mar 31, 2023 Add to My Watchlist
Press Releases about Zai Lab Ltd ADR
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
Zai Lab Announces Participation in January Investor Conferences
December 20, 2022
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2022
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors
Zai Lab Announces Participation in November Investor Conferences
October 31, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Zai Lab Limited (NASDAQ: ZLAB) Investor Alert: Investigation over Possible Violations of Securities Laws
April 25, 2022
San Diego, CA -- (SBWIRE) -- 04/25/2022 -- Zai Lab Limited is under investigation over potential securities laws violations by Zai Lab Limited in connection with certain financial statements.
Promising Developments in Breast Cancer Treatments Ahead in 2022
January 12, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following